Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
Interventional, Open-label, Flexible-dose, Long-term Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Sponsor: H. Lundbeck A/S
A PHASE3 clinical study on Major Depression Disorder, this trial is completed. The trial is conducted by H. Lundbeck A/S and has accumulated 9 data snapshots since 2015. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Completed PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- H. Lundbeck A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Allentown, United States , Arcadia, United States , Berlin, Germany , Bialystok, Poland , Bydgoszcz, Poland , Chełmno, Poland , Frankfurt, Germany , Gdansk, Poland , Hanover, Germany , Helsinki, Finland and 21 more locations